Smith, Salley & Associates Astrazeneca PLC Transaction History
Smith, Salley & Associates
- $1.84 Billion
- Q3 2025
A detailed history of Smith, Salley & Associates transactions in Astrazeneca PLC stock. As of the latest transaction made, Smith, Salley & Associates holds 136,228 shares of AZN stock, worth $12.2 Million. This represents 0.57% of its overall portfolio holdings.
Number of Shares
136,228
Previous 15,651
770.41%
Holding current value
$12.2 Million
Previous $1.09 Million
856.18%
% of portfolio
0.57%
Previous 0.07%
Shares
9 transactions
Others Institutions Holding AZN
# of Institutions
1,498Shares Held
500MCall Options Held
5.59MPut Options Held
3.18M-
Price T Rowe Associates Inc Baltimore, MD49.1MShares$4.39 Billion0.4% of portfolio
-
Primecap Management CO Pasadena, CA39.9MShares$3.56 Billion2.42% of portfolio
-
Bank Of America Corp Charlotte, NC32.6MShares$2.92 Billion0.18% of portfolio
-
Wellington Management Group LLP Boston, MA32.3MShares$2.89 Billion0.45% of portfolio
-
Capital International Investors Los Angeles, CA25.1MShares$2.24 Billion0.33% of portfolio
About ASTRAZENECA PLC
- Ticker AZN
- Exchange OTC
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 3,099,020,032
- Market Cap $277B
- Description
- AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, By...